scholarly journals Plasma cell acid phosphatase in multiple myeloma [letter; comment]

Blood ◽  
1993 ◽  
Vol 81 (3) ◽  
pp. 869-870
Author(s):  
P Musto
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Plasma Cell ◽  
Letter Comment ◽  
Cell Acid

Plasma cell acid phosphatase score in multiple myeloma and related disorders

1985 ◽  
Vol 59 (1) ◽  
pp. 67-72 ◽  
Author(s):  
J. J. M. L. Hoffmann ◽  
W. P. M. Breed ◽  
N. Swaak-Lammers
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Plasma Cell ◽  
Cell Acid

Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.

1985 ◽  
Vol 3 (11) ◽  
pp. 1503-1507 ◽  
Author(s):  
M Boccadoro ◽  
A Gallamini ◽  
A Fruttero ◽  
P Gavarotti ◽  
V Redoglia ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Prognostic Factor ◽  
Plasma Cell ◽  
Patient Survival ◽  
Labeling Index ◽  
Survival Duration ◽  
Monoclonal Gammopathies ◽  
Thymidine Labeling Index ◽  
Cell Acid

Plasma cell acid phosphatase (AP) activity and thymidine labeling index (LI%) were evaluated concomitantly in 52 patients with monoclonal gammopathies. AP score, percentage of AP positive plasma cells, and LI% were significantly higher in 26 patients with multiple myeloma (MM) at the time of diagnosis than in 11 monoclonal gammopathy of undetermined significance (MGUS) and eight smoldering myeloma (SM) patients. LI% had the highest statistical correlation with disease status. A 1% cutoff could clearly separate the patients with progressive MM compared to those with stable disease (SM-MGUS) (P less than .001). There was a significant overall correlation between the AP score and LI% (P less than .005). Since LI% is a recognized powerful prognostic factor, this correlation suggests that the AP score can also be a reliable test predicting patient survival duration. In addition, we identified a subgroup of IgG MM patients with very high tumor mass who had a low LI% but a high AP score. This was associated with very poor patient survival and indicated the discrete prognostic importance of AP score in this subgroup with low LI%. Thus, both the LI% and AP score can be recommended as helpful clinical tests in patients with monoclonal gammopathies.

Plasma Cell Acid Phosphatase and Prognosis in Multiple Myeloma

1994 ◽  
Vol 14 (5-6) ◽  
pp. 497-501 ◽  
Author(s):  
Pellegrino Musto ◽  
Saverio Fusilli ◽  
Mario Carotenuto
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Plasma Cell ◽  
Cell Acid

scholarly journals Prognostic correlation of plasma cell acid phosphatase and beta- glucuronidase in multiple myeloma: a Southwest Oncology Group study [see comments]

Blood ◽  
1991 ◽  
Vol 78 (12) ◽  
pp. 3281-3287 ◽  
Author(s):  
SM Saeed ◽  
D Stock-Novack ◽  
R Pohlod ◽  
J Crowley ◽  
SE Salmon
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Plasma Cell ◽  
Clinical Importance ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Southwest Oncology Group ◽  
Southwest Oncology Group Study ◽  
Patient Groups ◽  
Cell Acid

Abstract In 1982 a randomized trial of either alternating or syncopated VMCP/VBAP regimens for the treatment of active multiple myeloma was begun (Southwest Oncology Group Study 8229/30). A concurrent investigation was undertaken to evaluate the clinical importance and significance of cytochemically stainable plasma cell acid phosphatase (AP) and beta-glucuronidase enzymes (BG). Pretreatment bone marrow aspirates were available for analysis from 399 patients for AP and 398 patients for BG. The AP scores ranged between 42 and 395, and the BG scores ranged between 1 and 346. There was a significant increase of AP (P = .001) and BG (P = .002) in multiple myeloma as compared with a set of patients with benign plasmacytosis. The enzyme scores did not significantly relate to Ig idiotype of myeloma or other prognostic variables except that the BG scores varied significantly with the level of albumin (P = .03) and hemoglobin (P = .01). Analysis of patient groups with different levels of enzyme scores showed that 61 of 398 patients with an AP score of less than 130 had a poorer median survival of 1.7 versus 2.8 years for patients with higher scores (P = .001). In the multivariate analysis of survival, low AP score was an important prognostic factor (P = .006), but BG did not contribute significantly. It is suggested that the subset of patients presenting with low AP should be considered for specialized or more aggressive therapy.

scholarly journals Prognostic correlation of plasma cell acid phosphatase and beta- glucuronidase in multiple myeloma: a Southwest Oncology Group study [see comments]

Blood ◽  
1991 ◽  
Vol 78 (12) ◽  
pp. 3281-3287
Author(s):  
SM Saeed ◽  
D Stock-Novack ◽  
R Pohlod ◽  
J Crowley ◽  
SE Salmon
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Plasma Cell ◽  
Clinical Importance ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Southwest Oncology Group ◽  
Southwest Oncology Group Study ◽  
Patient Groups ◽  
Cell Acid

In 1982 a randomized trial of either alternating or syncopated VMCP/VBAP regimens for the treatment of active multiple myeloma was begun (Southwest Oncology Group Study 8229/30). A concurrent investigation was undertaken to evaluate the clinical importance and significance of cytochemically stainable plasma cell acid phosphatase (AP) and beta-glucuronidase enzymes (BG). Pretreatment bone marrow aspirates were available for analysis from 399 patients for AP and 398 patients for BG. The AP scores ranged between 42 and 395, and the BG scores ranged between 1 and 346. There was a significant increase of AP (P = .001) and BG (P = .002) in multiple myeloma as compared with a set of patients with benign plasmacytosis. The enzyme scores did not significantly relate to Ig idiotype of myeloma or other prognostic variables except that the BG scores varied significantly with the level of albumin (P = .03) and hemoglobin (P = .01). Analysis of patient groups with different levels of enzyme scores showed that 61 of 398 patients with an AP score of less than 130 had a poorer median survival of 1.7 versus 2.8 years for patients with higher scores (P = .001). In the multivariate analysis of survival, low AP score was an important prognostic factor (P = .006), but BG did not contribute significantly. It is suggested that the subset of patients presenting with low AP should be considered for specialized or more aggressive therapy.

Plasma Cell Acid Phosphatase as an Adjunct in the Differential Diagnosis of Monoclonal Immunoglobulinemias

1981 ◽  
Vol 65 (2) ◽  
pp. 103-107 ◽  
Author(s):  
Michele Tortarolo ◽  
Nicola Cantore ◽  
Mario Grande ◽  
Giuseppe Buonanno ◽  
Franco Dammacco
Keyword(s):  
Differential Diagnosis ◽  
Acid Phosphatase ◽  
Plasma Cell ◽  
Cell Acid

scholarly journals MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e046225
Author(s):  
Sarah Brown ◽  
Debbie Sherratt ◽  
Samantha Hinsley ◽  
Louise Flanagan ◽  
Sadie Roberts ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Plasma Cell ◽  
Phase Ii ◽  
Whole Body ◽  
Cell Leukaemia ◽  
High Dose ◽  
Newly Diagnosed ◽  
Genetic Changes ◽  
Novel Treatment

IntroductionMultiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately 20% of patients the tumour is characterised by genetic changes which confer a significantly poorer prognosis, generally termed high-risk (HR) MM. It is important to diagnose these genetic changes early and identify more effective first-line treatment options for these patients.Methods and analysisThe Myeloma UK nine OPTIMUM trial (MUKnine) evaluates novel treatment strategies for patients with HRMM. Patients with suspected or newly diagnosed MM, fit for intensive therapy, are offered participation in a tumour genetic screening protocol (MUKnine a), with primary endpoint proportion of patients with molecular screening performed within 8 weeks. Patients identified as molecularly HR are invited into the phase II, single-arm, multicentre trial (MUKnine b) investigating an intensive treatment schedule comprising bortezomib, lenalidomide, daratumumab, low-dose cyclophosphamide and dexamethasone, with single high-dose melphalan and autologous stem cell transplantation (ASCT) followed by combination consolidation and maintenance therapy. MUKnine b primary endpoints are minimal residual disease (MRD) at day 100 post-ASCT and progression-free survival. Secondary endpoints include response, safety and quality of life. The trial uses a Bayesian decision rule to determine if this treatment strategy is sufficiently active for further study. Patients identified as not having HR disease receive standard treatment and are followed up in a cohort study. Exploratory studies include longitudinal whole-body diffusion-weighted MRI for imaging MRD testing.Ethics and disseminationEthics approval London South East Research Ethics Committee (Ref: 17/LO/0022, 17/LO/0023). Results of studies will be submitted for publication in a peer-reviewed journal.Trial registration numberISRCTN16847817, May 2017; Pre-results.

Sign in / Sign up

Export Citation Format

Share Document